Schizophrenia Research
Volume 63, Issue 3 , Pages 297-299 , 1 October 2003

Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia

  • Christian C Joyal

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-514-881-3764; fax: +1-514-881-3701.
    • Institut Philippe Pinel de Montréal, Research Center, 10 905, Henri-Bourassa E. boul., Montréal, Canada, H1C 1H1
    • ,
  • Paul Hallé

      Affiliations

    • Institut Philippe Pinel de Montréal, Research Center, 10 905, Henri-Bourassa E. boul., Montréal, Canada, H1C 1H1
    • ,
  • Dominique Lapierre

      Affiliations

    • Institut Philippe Pinel de Montréal, Research Center, 10 905, Henri-Bourassa E. boul., Montréal, Canada, H1C 1H1
    • ,
  • Sheilagh Hodgins

      Affiliations

    • Institut Philippe Pinel de Montréal, Research Center, 10 905, Henri-Bourassa E. boul., Montréal, Canada, H1C 1H1
    • Department of Psychology, Université de Montréal, Montréal, Canada

References 

  1. Andreasen NC, Flaum M, Swayze VW, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia. A critical reappraisal. Arch. Gen. Psychiatry. 1990;47:615–621
  2. Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol. Med. 1992;22:379–388
  3. Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT. Clinical correlates of the deficit syndrome of schizophrenia. Am. J. Psychiatry. 1990;147:290–294
  4. Buckley PB, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for Clozapine therapy. Am. J. Psychiatry. 1994;151:385–389
  5. Convit A, Volavka J, Czobor P, de Asis J, Evangelista C. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. Am. J. Psychiatry. 1994;151:49–56
  6. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry. 1991;148:224–230
  7. Gupta S, Rajaprabhakaran P, Arndt S, Flaum M, Andreasen N. Premorbid adjustment as a predictor of phenomenological and neurobiological indices in schizophrenia. Schizophr. Res. 1995;16:189–197
  8. Hodgins S, Côté G, Toupin J. Major mental disorder and crime: an etiological hypothesis. In:  Cooke D,  Forth A,  Hare RD editor. Psychopathy: Theory, Research, and Implications for Society. Dordrecht, The Netherlands: Kluwer Academic Publishing; 1998;p. 231–256
  9. Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT, et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr. Res. 1996;20:69–77
  10. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict. Behav. 1998;23:717–734
  11. Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Miles KM, Hill D. Substance use disorder in Hospitalized severely mentally ill psychiatric patients: prevalence, correlates and subgroups. Schizophr. Bull. 2000;26:179–192
  12. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511–2518
  13. Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr. Res. 2001;48:109–123
  14. Schanda H, Földes P, Topitz A, Fliedl R, Knecht G. Premorbid adjustment of schizophrenic criminal offenders. Acta Psychiatr. Scand. 1992;86:121–126
  15. Scheller-Guilkey G, Lewine RRJ, Brown CFW. Schizophrenia, substance use, and brain morphology. Schizophr. Res. 1999;35:113–120
  16. Zisook S, Heaton R, Moranville J, Kuck J, Jernigan T, Braff D. Past substance abuse and clinical course of schizophrenia. Am. J. Psychiatry. 1992;149:552–553

PII: S0920-9964(02)00387-0

doi: 10.1016/S0920-9964(02)00387-0

Schizophrenia Research
Volume 63, Issue 3 , Pages 297-299 , 1 October 2003

Article Tools